Pricing Log in Create free account
Friday 6 November 2026 Export BSX’s income statement to Excel — free account

Boston Scientific Corporation

BSX Healthcare Medical Devices

Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.

Revenue
+1.44%
EPS
−21.6%
Free cash flow
−25.3%
Total debt
+3.04%

Quarter to September 2026, against a year earlier

42.73 1.91 −4.28%
Market cap
$64.7B
P/E
18.7×
Fwd P/E
17.0×
Dividend yield
—
F-score
7/9
Altman Z
5.41
Beneish M
−2.49
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Boston Scientific Corporation 10-Q filed Nov 3, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 6:31 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 1, 2025: 3 added · 41 modified; 13 with only figures updated

  1. Modified · Three Months Ended September 30, 2025

    Our net sales for the secondthird quarter of 2025 were $5.0615.065 billion, compared to $4.1204.209 billion for the secondthird quarter of 2024. This increase of $941855 million, or 22.820.3 percent, included operational1 net sales growth of 21.619.4 percent and the positive impact of 12090 basis points from foreign currency fluctuations. Operational net sales growth included organic2 net sales growth of 17.415.3 percent and the positive impact of 420 basis points from certain acquisitions during the period for which there are less than a full period of comparable net sales. Those acquisitions included Silk Road Medical, Inc. (Silk Road Medical) and Axonics, Inc. (Axonics), during the third and fourth quarters of 2024, respectively, and Intera Oncology®, Inc. (Intera) during the second quarter of 2025. The increase in our net sales was primarily driven by strong commercial execution across our businesses, particularly in our Electrophysiology business unit, which was led by the rapid adoptioncontinued growth of our FarapulseTM Pulsed Field Ablation System which launched in the U.S. in 2024 and in our Watchman business unit, which was led by the adoption of concomitant procedures in the U.S. Refer to Quarterly Results and Business Overview for a discussion of our net sales by business.